Astrazeneca PLC (AZN)

AstraZeneca has started trading its ordinary shares on the NYSE for the first time, aligning its listings across New York, London and Stockholm under a harmonised structure.

Under a new agreement with CSPC Pharmaceuticals, AstraZeneca will advance eight programmes targeting obesity and weight-related conditions, initially progressing four assets through Phase I.

AstraZeneca PLC has notified of the voluntary withdrawal of its American Depositary Shares and certain debt securities from The Nasdaq Stock Market LLC.

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.

AstraZeneca has received US approval for Imfinzi combined with FLOT chemotherapy for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers.

AstraZeneca has confirmed a $2 billion investment to expand its manufacturing presence in Maryland, including a larger biologics facility in Frederick and a new clinical manufacturing site in Gaithersburg.